Cardinal Health has agreed to acquire the assets of privately held Biotech, an operator of PET cyclotrons and nuclear pharmacies in the Southwestern United States. Terms of the agreement were not disclosed.
The Dublin, Ohio-based Cardinal owns and operates a network of nearly 160 nuclear pharmacies and operates 26 cyclotron-based PET radiopharmaceutical manufacturing facilities. The facilities are registered with the FDA to manufacture PET imaging agents.
With the addition of Biotech's four nuclear pharmacies, Cardinal said it will expand its existing U.S. PET business to locations in Arizona, Nevada, New Mexico and Texas.
"In addition to their facilities across the Southwestern United States, Biotech's employees and intellectual property will be applicable to support our role in supporting new drug development," said John Rademacher, president and general manager of nuclear and specialty pharmacy services for Cardinal.